Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

MolMed S.p.A.

Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is an integrated company covering all functions, from discovery to proof of clinical efficacy.MolMed’s business strategy is based on five key points: Developing novel therapies by demonstrating proof of concept in small, well-defined patient populations with high unmet medical needs Extending the therapies to additional indications after clinical efficacy has been demonstrated Conducting late-stage clinical development of certain therapies for specialised indications Partnering with major biotech and pharma companies for late-stage clinical development and marketing of therapies for broader indications Assuring a constant supply of products in the pipeline through internal research, external research collaborations, and in-licensing


Contact Details:
via Olgettina, 58
Milan
20132
Italy
Tel:39 0221277.1
Fax:39 0221277.220
Email:info@molmed.com
WWW:

www.molmed.com/




Recent Publications by MolMed S.p.A.:

The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration.
The viral infectivity factor (Vif) is essential for HIV-1 infectivity and...
8th May, 2009
MolMed S.p.A., Milano, Italy. Blood. 2009 Apr 9;113(15):3443-52. Epub 2009 Feb 11.
DOI Direct Link
Human recombinant heat shock protein 70 affects the maturation pathways of dendritic cells in vitro and has an in vivo adjuvant activity.
Heat shock proteins (HSPs) are potent inducers of an antigen-specific...
9th August, 2008
Molmed S.p.A., via Olgettina 58, 20132 Milan, Italy. J Leukoc Biol. 2008 Jul;84(1):199-206. Epub 2008 May 2.
DOI Direct Link
Blocking HIV-1 Vif restores a natural mechanism of intracellular antiviral defense.
AIDS has become the greatest pandemic in the human history counting...
10th March, 2005
Molmed S.p.A., via Olgettina, 58, 20132 Milano, Italy. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Dec;4(4):257-63.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 349 times since April 2007, the link to the organisation's website has been followed 86 times

Search for more companies in Milan

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for MolMed S.p.A.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.